NiTi Challenges Surgical Staple Market
This article was originally published in Start Up
Executive Summary
Surgical staples underpin surgeries in every operating room in the country, and are, well, staples of the businesses of Ethicon Endo-Surgery and Covidien, which together control 95% of the US surgical staples market. But now, in colorectal, bariatric, and thoracic procedures, some of the most promising markets for surgical staples, a threat is entering from the wings. NiTi Surgical Solutions has begun selling an alternative to staples, with a platform that it calls BioDynamix Anastomosis Technology, by which it describes compression devices that adjust to an organ's diameter to promote healing that's as natural as possible.
You may also be interested in...
Covidien Set to Compete in Vascular Business
Covidien, following the acquisition of Vnus Medical Technologies and Bacchus Vascular, is establishing a global business unit focused on vascular surgery.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.